PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	21-32	immunoglobulin kappa variable 1-16	Homo sapiens	179-182	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	215-226	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	21-32	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	21-32	immunoglobulin kappa variable 1-16	Homo sapiens	207-210	
32063189-7	2020	Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity.	Ceftazidime	21-32	immunoglobulin kappa variable 1-16	Homo sapiens	207-210